We advance plasma-derived single blood factor programs with tightly integrated upstream design, downstream purification, and preformulation science under a robust development governance. Explore our parent framework: Pharmaceutical Development & Manufacturing › Drug Substance Development › Blood Factor Development.
Overview of Plasma-Derived Single Blood Factor Development
Developing a single factor from human plasma requires precise fractionation chemistry, orthogonal chromatography, and stability engineering that collectively deliver defined identity, purity, and potency attributes. We begin with qualified plasma pools and establish predictive, small-scale models that emulate cold ethanol fractionation or cryoprecipitate enrichment. Subsequent capture and polishing are selected for the factor's physicochemical profile—charge, hydrophobic patches, glycosylation, and conformational sensitivity—while activation and aggregation are actively constrained. Pathogen-reduction is embedded by design using complementary mechanisms (e.g., solvent/detergent, low-pH holds, pasteurization, nanofiltration) to demonstrate cumulative removal/inactivation without compromising structural integrity.
Our Services
Our services set covers: fractionation & capture, polishing with pathogen-reduction, analytical & reference standards, and stability engineering.
Fractionation & Capture Development Service
We design fractionation trains that respect protein tolerance to solvent, temperature, ionic strength, and shear. Options include cold ethanol schemes or cryo-enrichment followed by capture via ion-exchange, pseudo-affinity (e.g., heparin-like matrices where appropriate), or immuno-affinity. Bench-scale columns and scaled precipitation studies quantify capacity, selectivity, and elution gentleness while minimizing carryover of closely related plasma proteins.
Polishing & Pathogen-Reduction Integration Service
To refine purity and constrain activation, we configure orthogonal polishing (anion/cation exchange, HIC, mixed-mode) to remove fragments, activated species, and high–molecular weight aggregates. Pathogen-reduction steps—solvent/detergent, pasteurization, low-pH incubation, and nanofiltration—are integrated into the downstream sequence with small-scale validation that demonstrates additive reduction while maintaining potency. Compatibility screens verify that excipients, contact materials, and residence times do not trigger conformational drift or contact activation. We also profile resin lifetime, cleaning agents, and carryover risk to support later lifecycle decisions.
Analytical & Reference Standard Development Service
Our laboratories establish potency, identity, purity, and comparability methods aligned to the factor's structure-function. Typical packages include clotting or chromogenic potency, intact mass and peptide mapping, SEC-MALS for aggregates, targeted assays for activation markers, residual solvent/detergent quantification, and—if applicable—specialized tests such as multimer analysis (vWF) or heparin cofactor activity (antithrombin).
Stability Engineering Service
Accelerated and long-term stability programs, including forced-degradation stressors, reveal degradation pathways and inform formulation setting, and shelf-life projections.
Our Plasma-Derived Single Blood Factor Development Portfolio
Our services support the development of various plasma-derived single blood factors, including:
- Factor X (pdFX)
- Factor XI (pdFXI)
- Fibrinogen (Factor I)
- Antithrombin (AT)
- Protein C (PC)
- Protein S (PS)
- C1 esterase inhibitor (C1-INH)
- …
We integrate deep expertise in fractionation science, orthogonal purification strategies, embedded pathogen-reduction steps, and rational stability design into cohesive, end-to-end development programs for plasma-derived single-factor therapeutics. Our approach emphasizes process robustness, product safety, and consistent quality from early development through scale-ready execution.
Our CDMO team delivers assay-anchored prototypes supported by decision-grade data packages, enabling clear technical evaluation, risk-informed choices, and efficient progression to the next stage of development. Contact us to initiate a tailored development plan that aligns with your program objectives, regulatory expectations, and long-term manufacturing strategy.
Our products and services are for research use only.
